Safety Information
PrTrintellix® (vortioxetine) is indicated for the treatment of major depressive disorder (MDD) in adults.
The efficacy in providing symptomatic relief of MDD was demonstrated in double-blind, placebo-controlled trials of up to 8 weeks in duration. The efficacy in maintaining an antidepressant response for up to 24 weeks was demonstrated in a double-blind, placebo-controlled trial in patients with MDD who initially responded to 12-week acute, open-label treatment. Physicians who elect to use Trintellix for extended periods should periodically re-evaluate the usefulness of the drug for individual patients.
The lowest effective dose of 5 mg/day should always be used as the starting dose in elderly patients ≥65 years of age.
Not indicated in patients <18 years of age.
Consult the Trintellix Product Monograph for important information relating to adverse reactions, drug interactions and dosing information not discussed in this piece.
The product monograph is also available by calling 1-800-586-2325.
Reference: Trintellix Product Monograph. Lundbeck Canada Inc. August 4, 2021.